Who are S-1 & Oxaliplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TS-1, oxaliplatin, S-1 + Cisplatin (arm A).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-1-oxaliplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

S-1 & Oxaliplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S-1 & Oxaliplatin (S-1 & Oxaliplatin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoropyrimidine + platinum-based chemotherapy combination. Area: Oncology.

phase 3 Fluoropyrimidine + platinum-based chemotherapy combination Thymidylate synthase (S-1); DNA (oxaliplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

S-1 & Oxaliplatin (S-1 & Oxaliplatin) — The First Affiliated Hospital with Nanjing Medical University. S-1 is a combination of three components that inhibit thymidylate synthase and fluorodeoxyuridine monophosphate formation, while oxaliplatin is a platinum-based agent that forms DNA crosslinks, together providing synergistic cytotoxic effects against cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
S-1 & Oxaliplatin TARGET	S-1 & Oxaliplatin	The First Affiliated Hospital with Nanjing Medical University	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase (S-1); DNA (oxaliplatin)
TS-1, oxaliplatin	TS-1, oxaliplatin	Samsung Medical Center	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase; DNA (platinum crosslinking)
S-1 + Cisplatin (arm A)	S-1 + Cisplatin (arm A)	Taiho Pharmaceutical Co., Ltd.	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase (S-1); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoropyrimidine + platinum-based chemotherapy combination class)

Samsung Medical Center · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S-1 & Oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/s-1-oxaliplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab